Graphic: Shutterstock

Biotech bears are maul­ing stocks as 2022 opens on a bleak note for in­vestors

As the first month of 2022 draws to a close, one thing seems to be on every­one’s mind in the bio­phar­ma world: a bur­geon­ing bear mar­ket.

While in­fla­tion and sup­ply chain is­sues have sent the Dow Jones and S&P 500 tum­bling — and the Nas­daq en­ter­ing cor­rec­tion ter­ri­to­ry — in re­cent weeks, few sec­tors have been hit as hard as biotech. The Nas­daq biotech­nol­o­gy in­dex and the XBI, two promi­nent barom­e­ters of pub­lic biotech per­for­mances, are down 15% and 20% since the start of the year, re­spec­tive­ly, out­pac­ing each of the three ma­jor US in­dices’ down­swings as of Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.